Open Philanthropy recommended an investment of $4,000,000 in Kainomyx to develop and produce new drugs to treat malaria and other parasitic diseases, such as cryptosporidiosis and toxoplasmosis. If effective, the new drugs would act by inhibiting cytoskeletal proteins in malarial and other parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing resistance to existing treatments.
This follows our May 2020 investment and falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.
Grant investigators: Chris Somerville and Heather Youngs
This page was reviewed but not written by the grant investigators. Kainomyx staff also reviewed this page prior to publication.
Open Philanthropy recommended an investment of $1,999,999 in Kainomyx to develop and produce a new antimalarial drug. If effective, the new drug would act by inhibiting cytoskeletal proteins in malarial parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing artemisinin resistance to existing treatments.
This falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.
